Why Pernix Therapeutics (PTX) Soared to a One-Year High Today

NEW YORK (TheStreet) -- Pernix Therapeutics  (PTX) soared more than 35% to a one-year high of $6.10 on Wednesday after the pharmaceutical company announced it would acquire the U.S rights to Treximet in an agreement with GlaxoSmithKline  (GSK).

Treximet is used for the acute treatment of migraine attacks with or without aura in adults. Pernix announces it expects the acquisition to close no later than Aug. 1.

Pernix also said it expects pro forma total revenue for the full year 2015 to exceed $230 million and sees EBTIDA margin greater than 40%.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was up 32.71% to $5.68 at 12:02 p.m. Nearly 5 million shares had changed hands, well above the average volume of 393,211.

PTX Chart

PTX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

5 Stocks Under $10 Set to Soar

These 5 Stocks Are Breaking Out

5 Stocks Under $10 Set to Soar

Today's Weak On High Volume Stock: Pernix Therapeutics Holdings (PTX)

Pernix Therapeutics Holdings (PTX) Highlighted As Weak On High Volume